



**ASX Release**

## **Three Additional US Patents Granted**

**Melbourne, Australia - (16 March, 2017):** Clinical-stage oncology company Prescient Therapeutics Ltd (ASX: PTX) is pleased to announce the issue of three additional US patents.

The first, No 9,518,079, a platform method of treatment for identifying and treating a patient having a tumor with enhanced sensitivity to TCN.

TCN-P (tricitabine phosphate monohydrate), now known as PTX-200, is a potent small molecule inhibitor of the AKT pathway, which plays a key role in the development of many cancers, including breast, ovarian cancer as well as hematologic cancers such as acute myeloid leukemia.

The second patent, No 9,457,040, claims a method for treating esophageal adenocarcinoma which overexpresses Akt kinase.

The third patent, No 9,511,084, also claims a method for treating cancers which overexpress Akt in combination with trastuzumab.

The allowance of these latest patents in the US further bolsters PTX's intellectual property portfolio.

PTX-200 is currently in three US clinical trials for HER2- breast cancer; ovarian cancer, and acute myeloid leukemia.

**ENDS**

### **About Prescient Therapeutics Limited (PTX)**

PTX is a clinical stage oncology company developing novel compounds that show promise as potential new therapies to treat a range of cancers that have become resistant to front line chemotherapy.

PTX's lead drug candidate PTX-200 inhibits an important tumor survival pathway known as Akt, which plays a key role in the development of many cancers, including breast and ovarian cancer, as well as leukemia. Unlike other drug candidates that target Akt inhibition which are non-specific kinase inhibitors that have toxicity problems, PTX-200 has a novel mechanism of action that specifically inhibits Akt whilst being comparatively safer. This highly promising compound is now the focus of three current clinical trials. The first is a Phase 1b/2 trial evaluating PTX-200 as a new therapy for relapse and refractory Acute Myeloid Leukemia, being conducted at Florida's H. Lee Moffitt Cancer Center (Moffitt) and Yale Cancer Center in New Haven, Connecticut (Yale) under the leadership of Professor Jeffrey Lancet, MD.

PTX is also conducting a Phase 1b/2 study examining PTX-200 in breast cancer patients at the prestigious Montefiore Cancer Center in New York and the Moffitt. The third trial is a Phase 1b/2 trial of



PTX-200 in combination with current standard of care is also underway in patients with recurrent or persistent platinum resistant ovarian cancer at the Moffitt.

PTX's second novel drug candidate, PTX-100, is a first in class compound with the ability to block an important cancer growth enzyme known as geranylgeranyl transferase (GGT). It also blocks the Ral and Rho circuits in cancer cells which act as key oncogenic survival pathways, leading to apoptosis (death) of cancer cells. PTX-100 was well tolerated and achieved stable disease in a Phase I trial in advanced solid tumors.

**Further enquiries:**

Steven Yatomi-Clarke  
CEO & Managing Director  
Prescient Therapeutics Limited  
+61 417 601 440